Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

Microdosing glp-1 is gaining traction, but is it safe? Experts warn about compounded semaglutide, reduced efficacy, and ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...

More than 15.5 million Americans have tried weight loss injectables, but risks are rising with the proliferation of ...

Clinical neuroscientist Joe Schacht offered an overview of the research on weight-loss drugs for alcoholism, other potential ...

As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.

Novo Nordisk extended a four-day winning streak on Friday, adding 5.18 percent to close at $88.08 apiece as investors cheered ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...